Changing the mechanism of action may offer more durable disease control for patients with PsA who do not respond to an initial TNF inhibitor.

“We’re witnessing a renaissance in cytokine targeting,” says Dr. Emily Rhodes, immunologist at the Stanford Institute for Translational Medicine. “And TNF-α is still the most contested—and the most ...

BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...

Please provide your email address to receive an email when new articles are posted on . Patients treated with TNF inhibitors had respiratory hospitalization and mortality rates similar to patients on ...

Please provide your email address to receive an email when new articles are posted on . TNF inhibitors within 3 years of diagnosis had no statistically significant negative link with colorectal, lung ...

Exposure to antitumor necrosis factor (anti-TNF) therapy during the first 140 days of pregnancy is associated with a significant decrease in the risk of developing gestational diabetes (GD) among ...

Tumor necrosis factor (TNF) inhibitors led to no significant difference in survival or respiratory-related hospitalizations compared with non-TNF inhibitors, in patients with rheumatoid ...

A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn's disease. A new study published recently in the journal Gut shows children with Crohn's who ...